Get the Stockscreener App
1.3125
0.94%
-0.0125
After Hours:
1.31
-0.0025
-0.19%
Alterity Therapeutics Ltd Adr stock is traded at $1.3125, with a volume of 7,066.
It is down -0.94% in the last 24 hours and down -11.91% over the past month.
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.
See More
Previous Close:
$1.325
Open:
$1.345
24h Volume:
7,066
Relative Volume:
0.22
Market Cap:
$11.62M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-1.8507
EPS:
-0.7092
Net Cash Flow:
-
1W Performance:
+5.85%
1M Performance:
-11.91%
6M Performance:
-36.59%
1Y Performance:
-47.08%
1-Day Range:
$1.30
$1.35
1-Week Range:
$1.2101
$1.37
52-Week Range:
$1.01
$5.41
Alterity Therapeutics Ltd Adr Stock (ATHE) Company Profile
Name
Alterity Therapeutics Ltd Adr
Sector
Industry
Phone
-
Address
-
Alterity Therapeutics Ltd Adr Stock (ATHE) Latest News
Alterity Therapeutics discloses annual report for 2024 - Investing.com
Alterity Therapeutics announces regulatory notice filing - Investing.com
Alterity Therapeutics announces regulatory notice filing - Investing.com India
ATHE’s Stock Market Adventure: -14.26% YTD Growth Amidst Volatility - The InvestChronicle
Alterity reports positive Phase 2 trial interim data - Investing.com
Alterity Therapeutics announces trading halt - Investing.com
Alphabet stock cited by TD Cowen amid potential Wiz acquisition - Investing.com
Alterity Therapeutics announces trading halt By Investing.com - Investing.com
Avenue Supermarts stock target raised by Nuvama, still a Hold - Investing.com India
Wolfe Research keeps Peerperform rating on Goldman Sachs stock, notes mixed Q2 earnings - Investing.com India
RBC Capital sees growth potential in Bowhead Specialty shares - Investing.com
Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar - GlobeNewswire Inc.
Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study - GlobeNewswire Inc.
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review - GlobeNewswire Inc.
Appendix 4C – Q3 FY24 Quarterly Cash Flow Report - GlobeNewswire Inc.
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia - GlobeNewswire Inc.
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners - Stockhead
Alterity Therapeutics announces trading halt By Investing.com - Investing.com India
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting - GlobeNewswire Inc.
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session - Benzinga
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024 - GlobeNewswire Inc.
Check Up: Aussie biotech Avarax on the verge of peanut allergy cure; and recent ASX health winners - Stockhead
ASX Health Winners December: Health stocks beat market, look ‘undervalued’ going into 2024 - Stockhead
Closing Bell: The ASX is slightly higher, but not much cooler on Monday - Stockhead
Biotech ‘to be worth $US4 trillion’ - Daily Telegraph
Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) - PR Newswire
24 Stocks Moving in Friday's Pre-Market SessionAlterity Therapeutics (NASDAQ:ATHE) - Benzinga
ATHEAlterity Therapeutics Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection - Yahoo Finance
The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Sh - Benzinga
Check up: Enthusiasm rather than news is moving health stocks - Stockhead
The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger - Yahoo Finance
The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For An - Benzinga
54 Biggest Movers From YesterdayAcasti Pharma (NASDAQ:ACST), Alterity Therapeutics (NASDAQ:ATHE) - Benzinga
Alterity Therapeutics Ltd Adr Stock (ATHE) Financials Data
There is no financial data for Alterity Therapeutics Ltd Adr (ATHE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):